Publikationen
Publikationen von Frau Dr. Cengic:
1: Willhauck MJ, Sharif Samani BR, Klutz K, Cengic N, Wolf I, Mohr L, Geissler M, Senekowitsch-Schmidtke R, Göke B, Morris JC, Spitzweg C.
alpha-Fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.
Gene Ther. 2007 Nov 8; [Epub ahead of print]
PMID: 17989705 [PubMed - as supplied by publisher]
2: Unterholzner S, Willhauck MJ, Cengic N, Schütz M, Göke B, Morris JC, SpitzwegC.
Dexamethasone stimulation of retinoic Acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells.
J Clin Endocrinol Metab. 2006 Jan;91(1):69-78. Epub 2005 Oct 18.
PMID: 16234306 [PubMed - indexed for MEDLINE]
3: Cengic N, Baker CH, Schütz M, Göke B, Morris JC, Spitzweg C.
A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression.
J Clin Endocrinol Metab. 2005 Aug;90(8):4457-64. Epub 2005 Jun 7.
PMID: 15941870 [PubMed - indexed for MEDLINE]
4: Scholz IV, Cengic N, Baker CH, Harrington KJ, Maletz K, Bergert ER, Vile R, Göke B, Morris JC, Spitzweg C.
Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer.
Gene Ther. 2005 Feb;12(3):272-80.
PMID: 15510175 [PubMed - indexed for MEDLINE]
5: Auernhammer CJ, Kopp FB, Vlotides G, Dorn F, Isele NB, Spöttl G, Cengic N, Weber MM, Senaldi G, Engelhardt D.
Comparative study of gp130 cytokine effects on corticotroph AtT-20 cells--redundancy or specificity of neuroimmunoendocrine modulators?
Neuroimmunomodulation. 2004;11(4):224-32.
PMID: 15249728 [PubMed - indexed for MEDLINE]
6: Vlotides G, Sörensen AS, Kopp F, Zitzmann K, Cengic N, Brand S, Zachoval R, Auernhammer CJ.
SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA.
Biochem Biophys Res Commun. 2004 Jul 30;320(3):1007-14.
PMID: 15240148 [PubMed - indexed for MEDLINE]
7: Auernhammer CJ, Dorn F, Vlotides G, Hengge S, Kopp FB, Spoettl G, Cengic N, Engelhardt D, Weber MM.
The oncostatin M receptor/gp130 ligand murine oncostatin M induces apoptosis in adrenocortical Y-1 tumor cells.
J Endocrinol. 2004 Mar;180(3):479-86.
PMID: 15012602 [PubMed - indexed for MEDLINE]
8: Scholz IV, Cengic N, Göke B, Morris JC, Spitzweg C.
Dexamethasone enhances the cytotoxic effect of radioiodine therapy in prostate cancer cells expressing the sodium iodide symporter.
J Clin Endocrinol Metab. 2004 Mar;89(3):1108-16.
PMID: 15001595 [PubMed - indexed for MEDLINE
9: Auernhammer CJ, Isele NB, Kopp FB, Spoettl G, Cengic N, Weber MM, Senaldi G, Engelhardt D.
Novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) stimulates corticotroph function via a signal transducer and activator of transcription-dependent mechanism negatively regulated by suppressor of cytokine signaling-3.
Endocrinology. 2003 Apr;144(4):1202-10.
PMID: 12639901 [PubMed - indexed for MEDLINE]
Bücher
Koautor | |
2007 |
Fragen und Antworten zum Mammakarzinom (Kapitel: Nicht invasive Karzinome) http://www.tumorzentrum-muenchen.de/fileadmin/Downloads/Ratgeber_Mamma.pdf |
2007 | Manual Mammakarzinome (Kapitel: Klinik der In-situ- Karzinome) |
Wissenschaftliche Erfahrung
16.09.2003-21.09.2003 | Teilnahme am 75th Annual Meeting of the ATA Palm Beach - Poster A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression |
31.08.2004-04.09.2004 | Teilnahme am 12th International Congress of Endocrinology Lisabon. Radioiodine therapy of adrenocortical cancer following ACTH-receptor promoter-driven expression of the sodium iodide Symporter |
2004 | Teilnahme am International Congress of Endocrinology Vancouver |
2014 | Teilnahme am 30th Annual Meeting of ESHRE-Munich 2014 Is the giving of DHEA to poor responders top or flop? |
Publikationen von Herrn Dr. Zachmann:
/view/data/7212/Publikationen%20Zachmann.pdf